Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

被引：1
|
作者：
Ciccarese, C. [1 ]
Porcari, S. [2 ]
Buti, S. [3 ]
Fornarini, G. [4 ]
Primi, F. [5 ]
Giudice, G. C. [6 ]
Damassi, A. [7 ]
Berrios, J. R. Giron [8 ]
Stumbo, L. [9 ]
Arduini, D. [1 ]
Severino, A. [10 ]
Rondinella, D. [10 ]
Masucci, L. [10 ]
Sanguinetti, M. [10 ]
Gasbarrini, A.
Cammarota, G. [2 ,11 ]
Segata, N. [12 ]
Tortora, G. [13 ]
Ianiro, G. [10 ]
Iacovelli, R. [14 ]
机构：
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCC, Dept Med & Surg Sci UOC Gastroenterol, Rome, Italy
[3] Univ Parma, Univ Hosp Parma, Dept Med & Surg, Med Oncol Unit, Parma, Italy
[4] IRCCS Osped Policlin San Martino, Dept Hematol Oncol, Genoa, Italy
[5] Osped Belcolle ASL Viterbo, Oncol, Viterbo, Italy
[6] Univ Parma, Oncol Med, Parma, Italy
[7] Asl3 Genovese, Med Oncol, Genoa, Italy
[8] Osped Belcolle ASL Viterbo, Med Oncol, Viterbo, Italy
[9] Azienda Osped Univ S Andrea, Med Oncol, Rome, Italy
[10] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Med & Surg Sci UOC Gastroen terol, Rome, Italy
[11] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCC, Dept Internal Med & Gastroenterol, Rome, Italy
[12] Univ Trento, Dipartimento Biol Cellulare Computaz Integrata CI, Cellular Computat & Integrat Biol CIBIO, Povo, Italy
[13] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[14] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2320
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA77
引用
收藏
页码：1264 / 1264
页数：1
相关论文
共 50 条
  • [31] PHASE II TRIAL OF NEOADJUVANT AXITINIB IN PATIENTS WITH LOCALLY ADVANCED NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA
    Karam, Jose
    Devine, Catherine
    Urbauer, Diana
    Lozano, Marisa
    Maity, Tapati
    Ahrar, Kamran
    Tamboli, Pheroze
    Tannir, Nizar
    Wood, Christopher
    JOURNAL OF UROLOGY, 2014, 191 (04): : E646 - E646
  • [32] A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts
    Atkins, Michael B.
    Voss, Martin Henner
    Plimack, Elizabeth R.
    Rini, Brian I.
    Alter, Robert
    Dawson, Nancy Ann
    Beck, J. Thaddeus
    Bhatt, Rupal Satish
    Pappas, Kristen M.
    Wilson, Dawn
    McClure, Ty
    Kumar, Ravi
    Attie, Kenneth M.
    Sherman, Matthew L.
    Pandya, Shuchi Sumant
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component
    Park, Inkeun
    Lee, Hyo Jin
    Bae, Woo Kyoon
    Yoon, Shinkyo
    Lee, Jae Lyun
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (06) : 1239 - 1246
  • [34] A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component
    Inkeun Park
    Hyo Jin Lee
    Woo Kyoon Bae
    Shinkyo Yoon
    Jae Lyun Lee
    Investigational New Drugs, 2019, 37 : 1239 - 1246
  • [35] Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
    Fayette, J.
    Thomas, G.
    Daste, A.
    Rotarski, M.
    Castelo, B.
    Rullan, A.
    Levine, A.
    Philipson, R. S.
    Harrington, K. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S615 - S616
  • [36] Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
    Brian I. Rini
    David I. Quinn
    Michael Baum
    Laura S. Wood
    Jamal Tarazi
    Brad Rosbrook
    Lillian Shahied Arruda
    Laura Cisar
    W. Gregory Roberts
    Sinil Kim
    Robert J. Motzer
    Targeted Oncology, 2015, 10 : 45 - 53
  • [37] Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
    Rini, Brian I.
    Quinn, David I.
    Baum, Michael
    Wood, Laura S.
    Tarazi, Jamal
    Rosbrook, Brad
    Arruda, Lillian Shahied
    Cisar, Laura
    Roberts, W. Gregory
    Kim, Sinil
    Motzer, Robert J.
    TARGETED ONCOLOGY, 2015, 10 (01) : 45 - 53
  • [38] Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial)
    Duttagupta, Sreya
    Messaoudene, Meriem
    Jamal, Rahima
    Mihalcioiu, Catalin
    Belanger, Karl
    Lenehan, John
    Belkaid, Wiam
    Parvathy, Seema Nair
    Maillou, Jade
    Hu, Yongjia
    Ponce, Mayra
    Hakozaki, Taiki
    Salazar, Eder Mendez
    Silverman, Michael
    Vareki, Saman Maleki
    Elkrief, Arielle
    Routy, Bertrand
    CANCER RESEARCH, 2024, 84 (07)
  • [39] Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
    Kessler, Elizabeth R.
    Hu, Junxiao
    Srivastava, Geetika
    Kemme, Douglas Jerome
    Iruku, Praveena
    Rana, Vishal
    Schuster, Steven Robert
    Amirault, Mali
    Callihan, Eryn
    Flaig, Thomas W.
    Lam, Elaine Tat
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] HEALTH STATE UTILITIES IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE PEMBROLIZUMAB PLUS AXITINIB OR SUNITINIB
    Bensimon, A.
    Lai, Y.
    Xu, R.
    Bhattacharya, R.
    Shinde, R.
    VALUE IN HEALTH, 2022, 25 (07) : S554 - S554
12345